Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 12-Month Low - Time to Sell?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $54.95 and last traded at $54.95, with a volume of 350 shares. The stock had previously closed at $56.11.

Wall Street Analysts Forecast Growth

Separately, William Blair raised shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.

Zealand Pharma A/S Price Performance

The company has a 50 day simple moving average of $65.19 and a 200 day simple moving average of $81.24. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of -23.19 and a beta of 0.68. The company has a quick ratio of 25.07, a current ratio of 25.10 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. The business had revenue of $1.14 million during the quarter, compared to analysts' expectations of $248.61 million. As a group, research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.